Skip to main content
Fig. 1 | BMC Medical Genetics

Fig. 1

From: ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients

Fig. 1

Cumulative proportion surviving of HD patients with respect to selected ENHO and LXRA SNPs. a Cardiovascular mortality among HD patients showing atherogenic dyslipidemia with respect to ENHO rs2281997 polymorphic variants (the dominant model of inheritance). Cardiovascular mortality was analyzed among 227 patients who started the prospective study showing atherogenic dyslipidemia. Through 7.5 years of follow-up, 86 patients died due to cardiovascular complications (43 subjects possessed the CC genotype and 43 patients were harboring the T allele of ENHO rs2281997). Cardiovascular mortality was analyzed using the Kaplan-Meier method with the subsequent log-rank test. In the Cox analysis, the T allele was associated with approximately 1.6-fold lower cardiovascular mortality in HD patients with atherogenic dyslipidemia (HR 0.64, 95% CI 0.42 - 0.99, P = 0.047). b Survival probability in HD patients with respect to LXRA rs2279238 polymorphic variants (the dominant model of inheritance). Survival probability was analyzed using the Kaplan-Meier method in 440 patients prospectively followed through 7.5 years. In the Cox analysis, HR was 1.30, 95% CI 1.01 - 1.67, P = 0.042. c Survival probability in HD patients with respect to LXRA rs7120118 polymorphic variants (the dominant model of inheritance). Survival probability was analyzed using the Kaplan-Meier method in 440 patients prospectively followed through 7.5 years. In the Cox analysis, HR was 1.29, 95% CI 1.02 - 1.65, P = 0.037. d Survival probability in HD patients with respect to LXRA rs11039155 polymorphic variants (the dominant model of inheritance). Survival probability was analyzed using the Kaplan-Meier method in 440 patients prospectively followed through 7.5 years. In the Cox analysis, HR was 1.36, 95% CI 1.05 - 1.75, P = 0.016

Back to article page